Abstract Library

#1939 Antiproliferative Effects of Lanreotide in Neuroendocrine Tumors

Introduction: Neuroendocrine tumors of the lung (BP-NETs, typical (AC) and atypical Carcinoids (ATC)) are rare tumors with heterogeneous behavior and molecular characteristics. For the intermediate proliferating BP-NETs treatment options are limited and unsatisfactory. Somatostatin analogues have not only anti-secretory effects, but also display antiproliferative features, as shown by PROMID and CLARINET trial. Nevertheless, their value in BP-NET is undefined so far.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Grabowski P

Authors: Lelek S, Sedding D, Benecke J, Siegmund B, Schrader J,

Keywords: Bronchopulmonary neuroendocrine tumors (BP-NET), somatostatin analogues, Lanreotide, signaling,

#1869 Synergistic Effects of Combining Hsp90 and PI3K Inhibitors with Everolimus in Pancreatic Neuroendocrine Tumors

Introduction: The development of the first molecular targeted therapies for neuroendocrine tumors (NET) was a milestone in the treatment of patient. Nevertheless, these therapies eventually fail and patients become resistant to the treatment. One way of escaping this dilemma might be the combination of targeted drugs to prevent resistance development.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Schrader J

Authors: Weissmann V, Benten D, Fahl M, Eggers C, Izbicki J,

Keywords: targeted therapies, mTOR,

#1542 Selective Inhibition of PI3Kalpha (BYL719) - Promising Therapeutic Option for Neuroendocrine Tumors?

Introduction: Neuroendocrine tumors are heterogeneous, often functional malignancies and their therapeutic options are limited. As the PI3 kinase signaling is ­in GEP-NENs, selective PI3Kalpha inhibitors may be more potent than panPI3K inhibitors.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Grabowski P

Authors: Nölting S, Rentsch J, Freitag H, Briest F, Schrader J,

Keywords: PI3Kalpha, BYL719, neuroendocrine tumor cell lines,

#921 Combined Therapy with RAD001 e BEZ235 Overcomes Resistance of PET Cells to mTOR Inhibition

Introduction: Since the PI3K/Akt/mTOR proliferation axis is often deregulated in PETs, the mTORC1 complex inhibitor Everolimus (RAD001) represents an effective treatment for PETs. However, RAD001 leads to a re-activation of PI3K activity and phosphorylation of Akt, which may promote resistance to the treatment. Thus, direct inhibition of PI3K may represent a novel potential target for PETs.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Passacantilli I, Capurso G, Archibugi L, Calabretta S, Delle Fave G,

Keywords: mTOR, PI3K, resistance,